Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2016187426) A DEVICE THAT DELIVERS A SUSTAINED LOW-DOSE OF A MYOPIA-SUPPRESSING DRUG
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2016/187426 International Application No.: PCT/US2016/033279
Publication Date: 24.11.2016 International Filing Date: 19.05.2016
Chapter 2 Demand Filed: 10.03.2017
IPC:
A61F 2/14 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
F
FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
2
Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
02
Prostheses implantable into the body
14
Eye parts, e.g. lenses, corneal implants; Artificial eyes
Applicants:
AMORPHEX THERAPEUTICS LLC [US/US]; 5605 Riggins Court, Suite 200 Reno, NV 89502, US
Inventors:
LEAHY, Charles, D.; US
ELLIS, Edward, J.; US
Agent:
ELLIS, Edward, J.; US
Priority Data:
62/163,53419.05.2015US
Title (EN) A DEVICE THAT DELIVERS A SUSTAINED LOW-DOSE OF A MYOPIA-SUPPRESSING DRUG
(FR) DISPOSITIF DE DISTRIBUTION DE FAIBLE DOSE PROLONGÉE DE MÉDICAMENT DE SUPPRESSION DE MYOPIE
Abstract:
(EN) A non-degradable topical ocular drug delivery device includes about 0.001 % to about 10% w/w of at least one myopia-suppressing agent complexed with an immobile acid within a crosslinked polymer matrix. The cross-linked polymer matrix is configured to deliver the least one myopia- suppressing agent over an extended period of time at a concentration and rate that controls myopia progression while preserving pupillary function and accommodation.
(FR) L'invention concerne un dispositif d'administration de médicament oculaire topique non-dégradable, qui comprend d'environ 0,001 % à environ 10 % en poids d'au moins un agent de suppression de myopie complexé avec un acide immobile dans une matrice polymère réticulée. La matrice polymère réticulée est conçue pour administrer l'au moins un agent de suppression de myopie pendant une période de temps prolongée à une concentration et un taux qui contrôle la progression de myopie tout en préservant l'activité et la taille pupillaire.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)